Comments
Natco Pharma on Monday said it has received approval from the USFDA to market Lanthanum Carbonate chewable tablets used in the treatment of patients with end-stage renal disease. Its first generic product will be launched in the US soon. Fosrenol tablets had sales of $122.4 million during June 2017 in the US.
Natco and Lupin had entered into a pact in 2008 to jointly commercialise the generic equivalents of Fosrenol chewable tablets.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.